ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular Therapeutics”, “ImmunoCellular”, or the Company”) (NYSE MKT: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that it is scheduled to ring The Opening Bell at the New York Stock Exchange (NYSE) on Thursday, July 19th ,2012 to commemorate the Company’s recent up-listing to the NYSE MKT. ImmunoCellular’s common stock began trading on the NYSE exchange May 30th, 2012.
About ImmunoCellular Therapeutics, Ltd.
ImmunoCellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company has commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. To learn more about the Company, please visit www.imuc.com.
Forward-Looking Statements for ImmunoCellular Therapeutics